Biden administration to release prices for first 10 drugs subject to landmark Medicare negotiations
It is a milestone in a controversial process that aims to make costly medications more affordable for older Americans but
Read MoreIt is a milestone in a controversial process that aims to make costly medications more affordable for older Americans but
Read MoreRo said it hopes its new tool will be able to help patients understand their GLP-1 coverage options so they
Read MoreModerna now expects 2024 product revenue to come in between $3 billion and $3.5 billion, down from a previous guidance
Read MoreThe study results on Leqembi, which Eisai shares with Biogen, also found that Alzheimer's patients who take the therapy get
Read MoreThe drugmaker raised its full-year sales forecast to $63.4 billion to $64.4 billion on increased demand for key products, particularly
Read MoreQuestions about whether Eli Lilly and Novo Nordisk can maintain their duopoly in weight loss drugs are fair game, but
Read MoreThe committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with
Read MoreThe results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 and reinvest that money into
Read MoreNovo Nordisk's Wegovy has received backing from the EU's medical regulator to expand the weight loss drug's use to reducing
Read More